Intra-Cellular Therapies, Inc. (ITCI) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Sharon Mates.
ITCI tiene fecha de IPO 2014-01-07, 860 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $14.05B.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company headquartered in New York that develops novel medications for neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms in the central nervous system. The company's approved product CAPLYTA treats schizophrenia in adults, while its clinical pipeline includes lumateperone in Phase III trials for bipolar depression and autism spectrum disorder, Lenrispodun for Parkinson's disease and heart failure, ITI-1284-ODT-SL for dementia-related behavioral disturbances, and ITI-333 for substance use disorders and psychiatric conditions. Founded in 2002, the company focuses on addressing significant unmet medical needs in the neuropsychiatric market through innovative drug development.
